Shanghai, China – Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the 10th Oriental Congress of Cardiology ("OCC 2016") in Shanghai Expo Center, to further prove the safety and efficacy of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") by sharing results and cases of its TARGET Serial Clinical Trials with a satellite meeting. The OCC 2016 was hosted by Shanghai Medical Association and Chinese Society of Cardiology, focusing on the latest treatment and studies of cardiovascular diseases, with lectures and operation demonstrations by domestic and overseas experts.
The satellite meeting, themed on "Firehawk® TARGET Serial Clinical Trial Outcome," was chaired by Professor Juying Qian of Zhongshan Hospital, who is also the Secretary of the OCC 2016, Professor Haichang Wang of Tangdu Hospital & the Second Affiliated Hospital of the Fourth Military Medical University, Professor Zheng Zhang of the First Hospital of Lanzhou University, Professor Haibo Liu of Fuwai Hospital of Chinese Academy of Medical Sciences, and Professor Qiming Wu of Beijing Ditan Hospital Capital of Medical University. Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Li Sheng of the First Affiliated Hospital of Harbin Medical University, Professor Haiyan Wang of Tangdu Hospital & the Second Affiliated Hospital of the Fourth Military Medical University, and Professor Sanbin Xu of Shanghai Putuo District Central Hospital, were invited as keynote speakers.
During the conference, Professor Bo Xu analyzed in-depth the four-year follow-up data of Firehawk® TARGET Clinical Research, and noted that Firehawk® marks a milestone in the field of drug-eluting stent ("DES"), almost impossible to be surpassed by other stents. According to the results of TARGET Serial Clinical Trials, Firehawk® is especially safe and effective for patients with medium- and low-risk. Besides, Firehawk®'s large-scale Clinical Trial in Europe – TARGET All Comer, has successfully enrolled over 500 patients within the first few months after its launch, making it possible to collect more evidence to prove Firehawk®'s safety and efficacy. Professor Qian said:" Firehawk® features outer-surface grooves, target-eluting design, and low drug dosage, and makes a perfect balance between the occurrence of in-stent restenosis and late thrombosis. Its cumulative incidence rate of thrombosis in four years is merely 0.4%, which is very low compared to other stents."
Afterwards, several experts shared their experience in using Firehawk®, to demonstrate its outstanding performance in clinical applications to the attendees. Professor Li Sheng shared a case of successfully treating iatrogenic stent deformation – at first, he implanted a stent of other brand, which was ineffective, and then he implanted a 3.0*38mm Firehawk® with low profile and good crossability, which ultimately passed the lesion. Professor Haiyan Wang released a report regarding a case of a STEMI (ST-elevation myocardial infarction) patient with severe stenosis of left main stem – The patient, marked as a high-risk patient by the Grace Score, suffered from acute occlusion of anterior descending artery and terminal trigeminal lesion, and was implanted into a low-profile 3.0*23mm Firehawk®, which resulted in ideal TIMI (thrombolysis in myocardial linfarction) blood flow. One week after the second PCI (percutaneous coronary intervention) surgery, the patient was implanted into a 3.0*23mm Firehawk® in the circumflex branch of the left coronary artery, and a 4.0*23mm Firehawk® in the anterior descending branch of the left main stem. Professor Wang said:" Firehawk® is proved safe in treating patients with ACS (acute coronary syndrome) and complex lesions. I'm looking forward to the follow-up results." In the end, Professor Sanbin Xu shared a case of treating spontaneous dissection of the right coronary artery with Firehawk®, the result of which showed that Firehawk® has excellent crossability in the treatment of spontaneous dissection complex lesions. Professor Haibo Liu pointed out, Firehawk® is of good efficacy, as it has thin strut and the grooves are designed on the outer surface which lead to low occurrence rate of long-term catching up and long-term thrombus.
Meanwhile, MicroPort® hosted a discussion panel on complications during the section of "Coronary Intervention Forum." Doctors specialized in coronary intervention shared reports on related cases including one case of CTO (chronic total occlusion) lesion of right coronary artery PCI with right coronary sinus dissection, one case of decreased blood pressure during PCI operation, one case of acute inferior myocardial infarction with stent removal, and one case of complex coronary artery dissection. The cases were commented and discussed by the chairmen and speakers, which are expected to benefit attended doctors in terms of surgical technique and clinical applications.
During the OCC 2016, MicroPort® displayed its innovative products of various business segments including cardiovascular, electrophysiological and pacemaker devices, demonstrating MicroPort®'s strategic layout and major achievements of its diversified businesses. In particular, it was the first time for products like Columbus® 3D EP Navigation System ("Columbus®") to appear in OCC, which attracted the attention from many professionals. Domestic experts such as Professor Xiaofei Sun, Vice Chairman of Shandong Cardiac Pacing and Electrophysiology Committee, Professor Jingtian Peng, Member of the Standing Committee of Chinese Society of Cardiology of JiangXi Medical Association, and Professor Hong Wang of Jiangxi Provincial People's Hospital, visited MicroPort® booth, learnt about major features of Columbus® and tried stimulating Real-time Mapping ("RTM") and collecting ECG signals by the device. Columbus® was spoken highly for its smooth operating. After trying Columbus®, Professor Shufeng Li of the Second Affiliated Hospital of Harbin Medical University, showed his affirmation to the efforts of Shanghai MicroPort EP MedTech Co in developing domestic 3D technology, and offered suggestions for further improvements.
MicroPort® will keep striving for innovations and strengthening the cooperation with doctors to offer better solutions to patients.